Taysha Gene Therapies (NASDAQ:TSHA) Receives Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a $5.00 price objective on the stock.

TSHA has been the subject of several other reports. Chardan Capital reissued a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a report on Tuesday, August 13th. Canaccord Genuity Group decreased their price objective on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has a consensus rating of “Buy” and a consensus target price of $6.38.

Taysha Gene Therapies Trading Up 2.7 %

Shares of Taysha Gene Therapies stock opened at $2.27 on Tuesday. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 5.22. The stock has a market capitalization of $465.22 million, a PE ratio of 3.60 and a beta of 0.44. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The company’s fifty day simple moving average is $1.98 and its 200-day simple moving average is $2.39.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. During the same quarter in the previous year, the company posted ($0.38) earnings per share. As a group, equities analysts anticipate that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Institutional Trading of Taysha Gene Therapies

Several hedge funds have recently bought and sold shares of the stock. Creative Planning bought a new stake in shares of Taysha Gene Therapies in the third quarter worth about $28,000. China Universal Asset Management Co. Ltd. increased its stake in Taysha Gene Therapies by 79.4% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 39,417 shares of the company’s stock worth $79,000 after acquiring an additional 17,446 shares during the last quarter. Privium Fund Management B.V. raised its holdings in shares of Taysha Gene Therapies by 21.8% during the 3rd quarter. Privium Fund Management B.V. now owns 120,000 shares of the company’s stock worth $241,000 after acquiring an additional 21,500 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at approximately $48,000. Finally, Artal Group S.A. grew its holdings in shares of Taysha Gene Therapies by 0.7% in the first quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after purchasing an additional 24,444 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.